Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emmessar Biotech & Nutrition Ltd (BSE: 524768) declared its audited standalone results for FY25 along with Q4 FY25 numbers. Revenue from operations rose to Rs. 61.09 lakhs from Rs. 55.52 lakhs in FY24, a growth of about 10%. Total income grew modestly to Rs. 261.96 lakhs from Rs. 254.73 lakhs. Profit before tax improved to Rs. 95.82 lakhs from Rs. 81.26 lakhs. However, net profit after tax fell sharply to Rs. 31.61 lakhs from Rs. 65.11 lakhs, mainly because total tax expense jumped to Rs. 64.20 lakhs from Rs. 16.15 lakhs. Basic EPS dropped to Rs. 0.61 from Rs. 1.28. Q4 FY25 alone slipped into a loss of Rs. 6.86 lakhs against a profit of Rs. 27.00 lakhs in Q4 FY24. The statutory auditor V. Nagarajan & Co. issued an unmodified (clean) audit opinion, and no investor complaints were pending.
Despite better revenue and pre-tax profit, the steep drop in full-year PAT and EPS, plus a Q4 loss, is negative for shareholders. The clean audit opinion is reassuring, but the heavy tax outflow is the main drag on bottom-line performance.